GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » EV-to-Revenue

Cutia Therapeutics (HKSE:02487) EV-to-Revenue : 5.85 (As of Jun. 05, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cutia Therapeutics's enterprise value is HK$880.3 Mil. Cutia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was HK$150.5 Mil. Therefore, Cutia Therapeutics's EV-to-Revenue for today is 5.85.

The historical rank and industry rank for Cutia Therapeutics's EV-to-Revenue or its related term are showing as below:

HKSE:02487' s EV-to-Revenue Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0
Current: 5.9

HKSE:02487's EV-to-Revenue is ranked better than
56.65% of 1038 companies
in the Biotechnology industry
Industry Median: 7.985 vs HKSE:02487: 5.90

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-05), Cutia Therapeutics's stock price is HK$6.62. Cutia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was HK$0.73. Therefore, Cutia Therapeutics's PS Ratio for today is 9.03.


Cutia Therapeutics EV-to-Revenue Historical Data

The historical data trend for Cutia Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics EV-to-Revenue Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EV-to-Revenue
- - 7.45

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue - - - - -

Competitive Comparison of Cutia Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Cutia Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cutia Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cutia Therapeutics's EV-to-Revenue falls into.



Cutia Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Cutia Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=880.255/150.529
=5.85

Cutia Therapeutics's current Enterprise Value is HK$880.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cutia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was HK$150.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cutia Therapeutics  (HKSE:02487) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Cutia Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=6.62/0.733
=9.03

Cutia Therapeutics's share price for today is HK$6.62.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was HK$0.73.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cutia Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cutia Therapeutics (HKSE:02487) Business Description

Traded in Other Exchanges
N/A
Address
436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases.
Executives
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Fil Limited 2201 Interest of corporation controlled by you
Shen Nan Peng 2201 Interest of corporation controlled by you
Snp China Enterprises Limited 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund V, L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Holdco Q, Ltd 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you
Hsg Holding Limited 2201 Interest of corporation controlled by you
Ma Yun 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Aurora Cutis Limited 2301 Trustee

Cutia Therapeutics (HKSE:02487) Headlines

No Headlines